US Broker Ratings

Zhengye Biotechnology Holding L (ZYBT) Stock Analysis: Navigating Market Challenges with Strategic Insights

Zhengye Biotechnology Holding Limited (ZYBT), a key player in the healthcare sector focusing on the development and manufacture of veterinary vaccines, presents an intriguing case for investors looking to explore..

Varex Imaging Corporation (VREX) Investor Outlook: A Healthcare Stock with Over 116% Potential Upside

Varex Imaging Corporation (NASDAQ: VREX), a key player in the healthcare sector’s medical devices industry, presents a compelling case for investors with its substantial potential upside of over 116%. Headquartered..

Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on a Biotech Challenger with 119% Potential Upside

Tvardi Therapeutics, Inc. (TVRD) is a name that is capturing the attention of investors in the biotechnology sector, particularly those with an appetite for high-reward opportunities. With a market capitalization..

aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring the 258.80% Potential Upside

Investors with an eye on the biotechnology sector may find aTyr Pharma, Inc. (NASDAQ: ATYR) an intriguing proposition. This San Diego-based clinical-stage biotech company is pioneering therapies aimed at treating..

Nano-X Imaging Ltd (NNOX) Stock Analysis: A 73% Potential Upside in the Rapidly Evolving Medical Devices Sector

Nano-X Imaging Ltd (NNOX), a key player in the medical devices industry, has been making waves with its innovative approach to medical imaging. Headquartered in Petah Tikva, Israel, Nano-X develops..

Alumis Inc. (ALMS) Stock Analysis: Exploring a Potential 597.67% Upside in the Biotech Sector

Alumis Inc. (ALMS), a promising player in the biotechnology industry, is catching the attention of investors with its significant upside potential. With a market capitalization of $310.05 million and a..

Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring a 212.50% Potential Upside in the Biotechnology Sector

Heron Therapeutics, Inc. (HRTX) is making waves in the biotechnology sector, with its innovative approach to improving medical care through its proprietary drug delivery technology, Biochronomer. The company’s focus on..

Viant Technology Inc. (DSP) Stock Analysis: Eyeing a 66% Upside Potential with Robust Revenue Growth

Viant Technology Inc. (NASDAQ: DSP), an innovative player in the technology sector, has caught the attention of investors with its impressive revenue growth and potential upside. As an advertising technology..

Anbio Biotechnology (NNNN) Stock Analysis: A Closer Look at Its Impressive 104% Yearly Growth

In the fast-evolving landscape of medical technology, Anbio Biotechnology (NNNN) has carved out a niche for itself, offering innovative in vitro diagnostics (IVD) products to a global market. Based in..

Marti Technologies, Inc. (MRT): An Investor Outlook on Potential 97% Upside

Marti Technologies, Inc. (NASDAQ: MRT), a dynamic player in the technology sector, is capturing investor attention with its unique position in the software application industry. Headquartered in Istanbul, Turkey, Marti..

Sanara MedTech Inc. (SMTI) Stock Analysis: A Healthcare Innovator with 77% Potential Upside

Sanara MedTech Inc. (SMTI) offers an intriguing opportunity for investors keen on the healthcare sector, where innovation and growth potential often intersect. Based in Fort Worth, Texas, Sanara MedTech is..

Palvella Therapeutics, Inc. (PVLA)

⚠️ No article content returned.

..

Checkpoint Therapeutics, Inc. (CKPT) Stock Analysis: Is the 4.46% Upside Worth the Risk?

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is an intriguing player in the field of biotechnology, specializing in the development of innovative treatments for solid tumor cancers. With a market capitalization of..

Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: A Potential 261.67% Upside in the Biotech Sector

Cartesian Therapeutics, Inc. (RNAC), a promising player in the biotechnology sector, is capturing investor attention with its potential for a remarkable 261.67% upside. This clinical-stage company, headquartered in Frederick, Maryland,..

Vanda Pharmaceuticals Inc. (VNDA): Investor Outlook Reveals 179.62% Potential Upside Amidst Challenging Financials

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biotechnology company specializing in therapies for unmet medical needs, presents a mixed bag of opportunities and challenges for investors. With a current market capitalization..

Gossamer Bio, Inc. (GOSS) Stock Analysis: A Look at the 489% Potential Upside in Biotechnology

Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, has been making waves in the biotechnology sector with its promising developments in pulmonary arterial hypertension (PAH) treatments. With a market..

Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis: Unveiling 82% Potential Upside Amid Biotech Breakthroughs

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is drawing significant attention from investors as it navigates the complex landscape of biopharmaceutical innovation. With a robust focus on gastrointestinal diseases, Phathom’s recent developments..

Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 443% Potential Upside

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a San Diego-based biotechnology company, is making waves in the healthcare sector with its innovative approach to developing mRNA-based therapeutics. With a current market..

National Research Corporation (NRC) Stock Analysis: Exploring the 72.69% Return on Equity in a Competitive Healthcare Sector

National Research Corporation (NASDAQ: NRC) stands out in the healthcare sector through its innovative approach to health information services. Headquartered in Lincoln, Nebraska, the company provides critical analytics and insights..

TruBridge, Inc. (TBRG) Stock Analysis: Exploring a 27% Upside Potential

TruBridge, Inc. (NASDAQ: TBRG) is making waves in the healthcare sector, with its impressive array of health information services that cater to community hospitals, clinics, and healthcare systems both in..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds